Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.

Publication

Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.

Journal Paper/Review - Apr 29, 2024

Burmester Gerd R, Stigler Jayne, Rubbert-Roth Andrea, Tanaka Yoshiya, Azevedo Valderilio F, Coombs Derek, Lagunes Ivan, Lippe Ralph, Wung Peter, Gensler Lianne S

Citation

Burmester G, Stigler J, Rubbert-Roth A, Tanaka Y, Azevedo V, Coombs D, Lagunes I, Lippe R, Wung P, Gensler L. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials. Rheumatol Ther 2024; 11:737-753.

Type

Journal Paper/Review (English)

Journal

Rheumatol Ther 2024; 11

Publication Date

Apr 29, 2024

Issn Print

2198-6576

Pages

737-753

Brief description/objective

This integrated analysis of the phase 2/3 and phase 3 SELECT trials describes the safety profile of upadacitinib, an oral Janus kinase inhibitor, for up to 5 years of exposure across psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA) (including pooled axial spondyloarthritis [axSpA]).